Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radi ....Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radiolabelled compound and a deeper insight into the mode of action will enable development of ligands for positron emission tomography (PET) which will aid in the development of BNC375 as well as other alpha7 modulators.Read moreRead less
Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commerc ....Targeting particulate carriers to epithelial M cells. This project aims to develop and validate an advanced in vitro model of the human intestinal epithelium. The intestine-on-chip model should enable mechanistic studies of the uptake of nano- and micron-size particles by intestinal cells and deliver new insights into the way particulate carriers can be specifically targeted and transported across the intestinal epithelium. Project knowledge and technology are anticipated to generate new commercialisation opportunities in the oral delivery industry and ultimately, should drive the development of efficient oral formulations for biologics. The model should also reduce the need for animal studies.Read moreRead less
Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and i ....Engineering Hybrid Materials with Functional Bioactivity in the GI Tract. This project aims to use an advanced particle engineering approach to develop novel biomaterials with multifunctional activities in the gastrointestinal tract. The project expects to generate new fundamental knowledge of the key interfacial processes that control digestion and identify new pathways for modulating gut microbiome composition. By establishing structure-activity relationships through mechanistic in vitro and in vivo models, the knowledge gain will help guide material design for optimised bioactivity. Technology transfer of the lead formulation through quality by design manufacturing practice is anticipated to position the industry partner for future commercial opportunities within the nutraceutical sector.Read moreRead less
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent ....A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Read moreRead less